Prosecution Insights
Last updated: April 19, 2026
Application No. 17/641,493

POLYNUCLEOTIDE SYNTHESIS METHOD, KIT AND SYSTEM

Non-Final OA §112
Filed
Mar 09, 2022
Examiner
ZHANG, KAIJIANG
Art Unit
1684
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Oxford Nanopore Technologies PLC
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
2y 11m
To Grant
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
518 granted / 678 resolved
+16.4% vs TC avg
Strong +36% interview lift
Without
With
+35.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
28 currently pending
Career history
706
Total Applications
across all art units

Statute-Specific Performance

§101
6.3%
-33.7% vs TC avg
§103
26.5%
-13.5% vs TC avg
§102
24.5%
-15.5% vs TC avg
§112
26.6%
-13.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 678 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections 2. Claims 108-133 are objected to because of the following informalities: Claim 108, line 1: “synthesising” should be changed to “synthesi[[s]]zing” to correct the typographical error Claim 109, line 1: “A method according to claim 108” should be changed to “The [[A]] method according to claim 108” for more clarity Claim 110, line 1: “A method according to claim 109” should be changed to “The [[A]] method according to claim 109” for more clarity Claim 111, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 112, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 113, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 114, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 115, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 116, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 117, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 118, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 119, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 120, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 121, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 122, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 123, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 124, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 125, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 126, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 127, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 128, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 129, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 130, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 131, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 132, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Claim 133, line 1: “A method according to…” should be changed to “The [[A]] method according to…” for more clarity Appropriate correction is required. Claim Rejections - 35 USC § 112 3. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 4. Claims 108-133 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being incomplete for omitting essential elements, such omission amounting to a gap between the elements. See MPEP § 2172.01. The omitted elements are: (i) essential technical feature(s) associated with “incorporation of one or more nucleotides in a first ligation reaction by the action of an enzyme having ligase activity” and “incorporation of one or more nucleotides in a second ligation reaction by the action of an enzyme having ligase activity” (because an enzyme having ligase activity would not add just “one” nucleotide in a ligation reaction and such ligation reaction also requires some additional feature(s) not recited in claim 108); (ii) essential technical feature(s) that enables the incorporation of nucleotides in the two strands of the double-stranded polynucleotide to occur in two separate ligation reactions (i.e., a “first” ligation reaction and a “second” ligation reaction) rather than a single ligation reaction (Note that the “cleavage” step between the two ligation-based extending steps as recited in claim 114 would require a cleavage site which is totally undefined in either claim 108 or claim 114, even though the specification (e.g., see Figure 1B) discloses that a universal nucleotide (that is added together with the one or more nucleotides to be incorporated by ligation) serves as such a cleavage site). Conclusion 5. No claim is currently allowed. However, once the informality and 112 issues (as discussed in the objections and rejections above) are resolved, claims 108-133 will be allowable. The prior art does not teach or reasonably suggest the method of instant claim 108. Specifically, Milton et al. (WO 2018/134616 A1), regarded as the closest prior art reference, disclose an in vitro method of synthesizing a double-stranded polynucleotide having a predefined sequence, the method comprising performing cycles of synthesis wherein in each cycle, a first strand is extended by the incorporation of a nucleotide of the predefined sequence and the second strand which is hybridized to the first strand is extended by the incorporation of a nucleotide thereby forming a nucleotide pair with the incorporated nucleotide of the first strand (see page 2, line 13 – page 3, line 21; claims 1-4; Figures 1-2). However, the first strand is extended by the action of a polymerase in the method of Milton et al. (see page 3, lines 3-21; claim 4), unlike the method of instant claim 108 wherein both strands of the double-stranded polynucleotide are extended by the action of an enzyme having ligase activity. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAIJIANG ZHANG whose telephone number is (571)272-5207. The examiner can normally be reached Monday - Friday, 8:30 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached at 571-272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KAIJIANG ZHANG/Primary Examiner, Art Unit 1684
Read full office action

Prosecution Timeline

Mar 09, 2022
Application Filed
Jan 06, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600961
METHODS AND SYSTEMS FOR DROPLET-BASED SINGLE CELL BARCODING
2y 5m to grant Granted Apr 14, 2026
Patent 12595500
HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS
2y 5m to grant Granted Apr 07, 2026
Patent 12584169
COMPOSITIONS AND METHODS FOR IMPROVING SAMPLE IDENTIFICATION IN INDEXED NUCLEIC ACID LIBRARIES
2y 5m to grant Granted Mar 24, 2026
Patent 12584170
METHOD OF NANOPORE SEQUENCING OF CONCATENATED NUCLEIC ACIDS
2y 5m to grant Granted Mar 24, 2026
Patent 12571036
METHODS, DEVICES, AND SYSTEMS FOR ANALYTE DETECTION AND ANALYSIS
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+35.5%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 678 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month